You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

XIPERE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xipere, and when can generic versions of Xipere launch?

Xipere is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-one patent family members in eighteen countries.

The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xipere

A generic version of XIPERE was approved as triamcinolone acetonide by TARO on October 1st, 1986.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for XIPERE?
  • What are the global sales for XIPERE?
  • What is Average Wholesale Price for XIPERE?
Summary for XIPERE
International Patents:81
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 83
Patent Applications: 4,307
Drug Prices: Drug price information for XIPERE
What excipients (inactive ingredients) are in XIPERE?XIPERE excipients list
DailyMed Link:XIPERE at DailyMed
Drug patent expirations by year for XIPERE
Drug Prices for XIPERE

See drug prices for XIPERE

Pharmacology for XIPERE

US Patents and Regulatory Information for XIPERE

XIPERE is protected by three US patents and one FDA Regulatory Exclusivity.

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Bausch And Lomb Inc XIPERE triamcinolone acetonide SUSPENSION;INJECTION 211950-001 Oct 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bausch And Lomb Inc XIPERE triamcinolone acetonide SUSPENSION;INJECTION 211950-001 Oct 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bausch And Lomb Inc XIPERE triamcinolone acetonide SUSPENSION;INJECTION 211950-001 Oct 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 3 of 3 entries

International Patents for XIPERE

See the table below for patents covering XIPERE around the world.

CountryPatent NumberTitleEstimated Expiration
Australia 2013342275 Methods and devices for the treatment of ocular diseases in human subjects ⤷  Subscribe
Israel 242395 מערכת ושיטות להזרקה עינית (Apparatus and methods for ocular injection) ⤷  Subscribe
South Africa 201208069 METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 3 of 3 entries

XIPERE Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for XIPERE

Introduction to XIPERE

XIPERE (triamcinolone acetonide injectable suspension) is a groundbreaking pharmaceutical product developed by Clearside Biomedical, Inc. It is the first FDA-approved product for injection into the suprachoroidal space, specifically designed to treat macular edema associated with uveitis[3].

Approval and Regulatory Milestones

The approval of XIPERE in 2021 marked a significant milestone for Clearside Biomedical. This approval was accompanied by non-dilutive funding of $19 million from commercialization partners for approval and pre-launch milestones, which was crucial for advancing Clearside's clinical development pipeline[3].

Commercialization and Market Adoption

XIPERE is commercialized in the United States by Bausch + Lomb, a key partner of Clearside Biomedical. The commercialization efforts have included extensive outreach and training programs for retinal physicians. As of the fourth quarter of 2022, over 1,000 retinal physicians had been trained in the use of the SCS Microinjector for suprachoroidal delivery of XIPERE[1].

Market Access and Adoption

To facilitate better access and adoption, XIPERE was granted a new CPT code, which is expected to enhance its market penetration. This code helps in streamlining the reimbursement process, making the treatment more accessible to patients[4].

Financial Performance

License and Other Revenue

The financial performance of XIPERE is closely tied to the licensing agreements and milestone payments. In the fourth quarter of 2021, Clearside Biomedical received significant one-time milestone payments from XIPERE licensing partners, amounting to $25.7 million. However, in the fourth quarter of 2022, this revenue dropped to $330,000 due to the absence of such one-time payments[1].

For the full year 2022, the license and other revenue from XIPERE was $1.3 million, down from $29.6 million in 2021, primarily due to the same reason[1].

Operating Expenses and Net Loss

The operating expenses related to XIPERE, including research and development, cost of goods sold, and general and administrative expenses, have been significant. For the fourth quarter of 2022, research and development expenses increased to $5.0 million from $3.8 million in the fourth quarter of 2021, largely due to preclinical research program costs[1].

The net loss for the fourth quarter of 2022 was $9.7 million, compared to a net income of $18.7 million in the fourth quarter of 2021. This shift was primarily due to the higher license revenue in 2021[1].

Clinical Trials and Pipeline Development

Clearside Biomedical continues to advance its clinical pipeline, with a focus on CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD). The OASIS trial, a U.S.-based, open-label, dose-escalation Phase 1/2a clinical trial, has reported favorable safety data, durability, and biologic effect[1].

Collaboration and Licensing Agreements

In addition to the partnership with Bausch + Lomb, Clearside Biomedical has entered into a new exclusive, worldwide license agreement with BioCryst Pharmaceuticals to use the SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor, avoralstat, for the treatment and prevention of diabetic macular edema (DME). This agreement includes an upfront license fee of $5 million and potential milestone payments of up to $77.5 million[4].

Market Opportunity and Growth Potential

The market opportunity for XIPERE and other products utilizing the suprachoroidal space delivery method is significant. The approval of XIPERE has opened up new avenues for treating serious retinal diseases, and the ongoing clinical trials and partnerships are expected to further expand this market.

Competitive Landscape

Clearside Biomedical's proprietary SCS Microinjector and the approval of XIPERE have positioned the company as a leader in the delivery of therapeutics into the suprachoroidal space. The unique delivery method and the partnerships with major pharmaceutical companies like Bausch + Lomb and BioCryst Pharmaceuticals enhance the competitive edge of Clearside Biomedical in the ophthalmic drug market[1][4].

Financial Projections and Funding

Clearside Biomedical's financial trajectory is influenced by the milestones achieved in the commercialization of XIPERE and the progress of its clinical pipeline. The company has sufficient resources to fund its planned operations, partly due to the non-dilutive funding received from approval and pre-launch milestones.

As of December 31, 2022, Clearside Biomedical had cash and cash equivalents of $48.3 million, which, combined with anticipated milestone payments, is expected to support its operations into the future[1].

Key Takeaways

  • Approval and Commercialization: XIPERE is the first FDA-approved product for injection into the suprachoroidal space, treating macular edema associated with uveitis.
  • Financial Performance: Significant one-time milestone payments in 2021 contrast with lower revenue in 2022, reflecting the absence of such payments.
  • Clinical Pipeline: Ongoing trials for CLS-AX and new partnerships, such as with BioCryst Pharmaceuticals, indicate strong growth potential.
  • Market Opportunity: The unique delivery method and expanding partnerships position Clearside Biomedical for significant market growth.
  • Financial Projections: Sufficient funding to support ongoing operations and future growth.

FAQs

What is XIPERE and how is it administered?

XIPERE (triamcinolone acetonide injectable suspension) is administered via the suprachoroidal space using Clearside Biomedical's proprietary SCS Microinjector. It is the first FDA-approved product for this method of delivery, specifically treating macular edema associated with uveitis[3].

Who is the commercialization partner for XIPERE?

Bausch + Lomb is the commercialization partner for XIPERE in the United States. They have trained over 1,000 retinal physicians in the use of the SCS Microinjector[1].

What are the key financial highlights for XIPERE in 2022?

In 2022, Clearside Biomedical saw a significant decrease in license and other revenue from XIPERE, from $29.6 million in 2021 to $1.3 million, due to the absence of one-time milestone payments. The net loss for the fourth quarter of 2022 was $9.7 million[1].

What is the status of Clearside Biomedical's clinical pipeline?

Clearside Biomedical is advancing its clinical pipeline, particularly with the CLS-AX (axitinib injectable suspension) for wet AMD. The OASIS trial has reported favorable safety and efficacy data. Additionally, the company has entered into a new agreement with BioCryst Pharmaceuticals for the delivery of avoralstat using the SCS Microinjector[1][4].

How does the SCS Microinjector enhance the market position of Clearside Biomedical?

The proprietary SCS Microinjector positions Clearside Biomedical as a leader in the delivery of therapeutics into the suprachoroidal space. This unique method and the associated partnerships enhance the company's competitive edge in the ophthalmic drug market[1][4].

What are the financial resources available to Clearside Biomedical for future operations?

As of December 31, 2022, Clearside Biomedical had $48.3 million in cash and cash equivalents, along with anticipated milestone payments, which are expected to support its planned operations into the future[1].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.